Maxillofacial sarcomas: a ugandan epidemiological survey

Kamulegeya Adriane

.

DOI: 10.4236/ojst.2011.12009                

Abstract

We reviewed the case notes of 203 patients who were treated for sarcomas of the oral and maxillofacial region over a period of 5 years. There were 98 male cases (mean age 31.4 ± 12.8 years) and 105 female cases (mean age 29.3 ± 10.4). Kaposi’s sarcoma accounted for 82.8% cases, and rhabdomyosarcoma 6.9% followed by osteosarcoma and chondrosarcoma at 2.5% each. Except for Kaposi’s sarcoma, surgery in combination with radiotherapy and/or chemothe- rapy was the main stay of treatment. Survival data was not available for most of our patients.

Keywords

Maxillofacial Sarcomas, Kaposi’s Sarcoma, Maxillofacial Tumors, Head and Neck Tumors

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Sturgis, M.E. and Potter, O.B. (2003) Sarcomas of the head and neck region. Current Opinion in Oncology, 15, 239-252. doi:10.1097/00001622-200305000-00011
[2]	Ahmad, Z., Qureshi, A. and Khurshid, A. (2009) The practice of histopathology in a developing country: difficulties and challenges; plus a discussion on the te- rrible disease burden we carry. Journal of Clinical Pathology, 62, 97-101. doi:10.1136/jcp.2008.061606
[3]	American Cancer Society. (2008) Cancer Facts & Figures. American Cancer Society, Atlanta.
[4]	Boutayeb, A. and Boutayeb, S. (2005) The burden of non communicable diseases in developing countries. Inter- national Journal for Equity in Health, 4, 2. http://www.equityhealthj.com/content/4/1/2 doi:10.1186/1475-9276-4-2
[5]	Dillon, P., Maurer, H., Jenkins, J., Krummel, T., Parham, D., Webber, B. and Salzberg, A. (1992) A prospective study of nonrhabdomyosarcoma soft tissue sarcomas in the pediatric age group. Journal of Pediatric Surgery, 27, 241-245. doi:10.1016/0022-3468(92)90320-7
[6]	Gurney, J.G., Swensen, A.R. and Bulterys, M. (1999) Malignant bone tumors. In: Reis, L.A.G., Smith, M.A., Gurney, J.G., et al., Eds. Cancer incidence and survival among children and adolescents: United States SEER Program, 1975-1995. National Cancer Institute SEER Program. NIH Pub., Bethesda, No. 99-4649, 99-110.
[7]	Adebayo, T.E., Ajike, O.S. and Adebola. A. (2005) Maxillo-facial sarcomas in Nigeria. Annals of African Medicine, 4, 23-30.
[8]	Chidia, L.M., Swaleh, M.S. and Godiah. M.P. (2000) Sarcomas of the head and neck at Kenyatta National Hospital. East African Medical Journal, 77, 256-259.
[9]	Yamaguchi, S., Nagasawa, H., Suzuki, T., Fujii, E., Iwaki, H., Takagi, M. and Amagasa, T. (2004) Sarcomas of the oral and maxillofacial region: a review of 32 cases in 25 years. Clinical Oral Investigations, 8, 52-55. doi:10.1007/s00784-003-0233-4
[10]	Pandey, M., Chandramohan, K., Thomas, G., Mathew, A., Sebastian, P., Somanathan, T., Abraham, K.E., Rajan, B. and Krishnan Nair, M. (2003) Soft tissue sarcoma of the head and neck region in adults. International Journal of Oral and Maxillofacial Surgery, 32, 43-48. doi:10.1054/ijom.2001.0218
[11]	Parkin, M.D., Bray, F., Ferlay, J. and Pisani, P. (2005) Global Cancer Statistics, 2002. CA: Cancer Journal for Clinicians 55, 74-108. http://caonline.amcancersoc.org/cgi/content/full/55/2/74 doi:10.3322/canjclin.55.2.74
[12]	Ledergerber, B., Telenti, A. and Effer, M.(1999) Risk of HIV related Kaposi’s sarcoma and non-Hodgkin’s lymphoma with potent antiretroviral therapy: prospective cohort study. British Medical Journal, 319, 23-24.
[13]	Omar, J.M., Hamza, O.J., Matee, M.I., Simon, E.N., Kikwilu, E., Moshi, M.J., Mugusi, F., Mikx, F.H., Verweij, P.E. and van der Ven, A.J. (2006) Oral manifestations of HIV infection in children and adults receiving highly active anti-retroviral therapy [HAART] in Dar es Salaam, Tanzania. BMC Oral Health, 6, 12. doi: 10.1186/1472-6831-6-12. doi:10.1186/1472-6831-6-12
[14]	Ziegler, J.L. and Katongole-Mbidde, E. (1996) Kaposi’s sarcoma in childhood:an analysis of 100 cases from Uganda and relationship to HIV infection. International Journal of Cancer, 65, 200-203.
[15]	Orem, J., Otieno, W.M. and Remick, C.S. (2004) AIDS- associated cancer in developing nations. Current Opinion in Oncology, 16, 468-476. doi:10.1097/00001622-200409000-00010
[16]	Dupin, N. and Giudice, D.P. (2008) Treatment of kaposi sarcoma in the highly active antiretroviral therapy era. Clinical Infectious Diseases, 47, 418-420. doi:10.1086/589866
[17]	Dupont, C., Vasseur, E., Beauchet, A., Aegerter, P., Berthe, H., de Truchis, P., et al. (2000) Long-term effi- cacy on Kaposi’s sarcoma of highly active antiretroviral therapy in a cohort of HIV-positive patients. AIDS, 14, 987-993 doi:10.1097/00002030-200005260-00010
[18]	Herzog, E.C. (2005) Overview of sarcomas in the adolescent and young adult population. Journal of Pediatric Hematology/Oncology, 27, 215-218 doi:10.1097/01.mph.0000161762.53175.e4
[19]	Chidzonga, M. and Mahomva, L. (2007) Sarcomas of the oral and maxillofacial region: A review of 88 cases in Zimbabwe. British Journal of Oral and Maxillofacial Surgery, 45, 317-318. doi:10.1016/j.bjoms.2005.11.008
[20]	van der Waal, R. and van der Waal, I. (2007) Oral non-squamous malignant tumors; diagnosis and treatment. Medicina Oral, Patología Oral y Cirugía Bucal, 12, E486-91.